MicroRNA 19a (miR-19a)

MicroRNA 19a (miR-19a) is a highly conserved, small non-coding RNA that serves as a critical post-transcriptional regulator of gene expression [3, 12]. It is a prominent member of the miR-17-92 cluster, often referred to as "oncomiR-1" due to its potent oncogenic properties in various malignancies [1, 20]. miR-19a exerts its biological effects by binding to the 3' untranslated regions (UTRs) of target mRNAs, such as the tumor suppressor PTEN and SOCS1, leading to their degradation or translational repression [2, 4, 11]. This regulation promotes cell proliferation, inhibits apoptosis, and facilitates angiogenesis and metastasis in cancers such as breast, lung, and gastric cancer [4, 11, 20]. Beyond oncology, miR-19a plays significant roles in cardiovascular health, where its dysregulation is linked to acute myocardial infarction and atherosclerosis [10, 11]. Therapeutic strategies targeting miR-19a primarily involve the use of antisense oligonucleotides, such as antagomirs or locked nucleic acids, to neutralize its activity and restore the expression of suppressed tumor suppressor genes [4, 6, 21]. However, the clinical translation of these therapies faces challenges including off-target effects and the need for efficient delivery systems to prevent nuclease degradation [5, 13, 16].

Other names

MIR19AMIRN19Ahsa-mir-19amiR-19a-3pmiR-19a-5pC13orf25MIR17HGMIRH1MIRHG1

Antisense-mediated inhibition of microRNA activity to restore target gene expression